---
title: "Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Economic impact of diagnostic testing"
description: "Formulary evidence on Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Economic impact of diagnostic testing. Topics: Procedure codes for MECP2 testing; US payer coverage criteria: medical necessity of genetic testing; US laboratory list prices: pediatric hospital molecular diagnostics laboratory, 2026; US laboratory list prices: MECP2 Sanger sequencing at a genetics center; 2 further topics. 6 evidence topics quoted from 6 sources."
canonical: "https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/product-information-and-disease-description/economic-impact-of-diagnostic-testing"
published: "2026-11-15T20:23:41-05:00"
modified: "2026-11-15T20:23:41-05:00"
---

# Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Economic impact of diagnostic testing

<a id="heading-2.2.1.8.4"></a>

## 2.2.1.8.4 Economic Impact of Diagnostic Testing

<a id="topic-2.2.1.8.4-1"></a>

### Procedure codes for MECP2 testing

> “81302: MECP2 (methyl CpG binding protein 2) (e.g., Rett syndrome) gene analysis; full sequence analysis”
> “81303: MECP2 (methyl CpG binding protein 2) (e.g., Rett syndrome) gene analysis; known familial variant”
> “81304: MECP2 (methyl CpG binding protein 2) (e.g., Rett syndrome) gene analysis; duplication/deletion variants”

Source: [Blue Shield of California (2023)](https://blueshieldca.com/content/dam/bsca/en/provider/docs/medical-policies/Genetic-Test-Rett-Syndrome.pdf)

<a id="topic-2.2.1.8.4-2"></a>

### US payer coverage criteria: medical necessity of genetic testing

> “Genetic testing for Rett syndrome−associated genes (e.g., MECP2, FOXG1, or CDKL5) may be considered medically necessary to establish a genetic diagnosis of Rett syndrome in a child with developmental delay and signs/symptoms of Rett syndrome, when a definitive diagnosis cannot be made without genetic testing.”
> “Targeted genetic testing for a known familial Rett syndrome−associated variant may be considered medically necessary to determine carrier status of a mother or a sister of an individual with Rett syndrome.”
> “There are no studies that report direct evidence on the clinical utility of genetic testing for RTT.”

Source: [Blue Shield of California (2023)](https://blueshieldca.com/content/dam/bsca/en/provider/docs/medical-policies/Genetic-Test-Rett-Syndrome.pdf)

<a id="topic-2.2.1.8.4-3"></a>

### US laboratory list prices: pediatric hospital molecular diagnostics laboratory, 2026

| Test | CPT code | 2026 price | CPT code, known familial variant | 2026 price, known familial variant |
| --- | --- | --- | --- | --- |
| MECP2 sequencing | “81302” | “$685” | “81303” | “$225” |
| MECP2 deletion/duplication | “81304” | “$300” | “81303” | “$300” |

Source: [Nemours (2026)](https://www.nemours.org/content/dam/nemours/nemours-org/en/documents/molecular-diagnostic-lab-cpt-codes-and-billing.pdf)

<a id="topic-2.2.1.8.4-4"></a>

### US laboratory list prices: MECP2 Sanger sequencing at a genetics center

| Field | Quoted record |
| --- | --- |
| Turnaround time | “21 days” |
| Price | “$900” |
| CPT code | “81302” |
| Method | “This test is performed by Sanger sequencing.” |
| Ordering of deletion/duplication analysis | “Sequencing of the MECP2 gene and MLPA deletion/duplication analysis can be ordered concurrently, sequentially or separately.” |

Source: [Greenwood Genetic Center](https://ggc.org/tests/rett-syndrome-mecp2-sequencing/)

<a id="topic-2.2.1.8.4-5"></a>

### Next-generation sequencing: effect on turnaround and cost

> “A genetic study using NGS allows the study of a larger number of genes associated with RTT-like symptoms simultaneously, providing genetic study of a wider group of patients as well as significantly reducing the response time and cost of the study.”

Source: [Vidal et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5613000/)

<a id="topic-2.2.1.8.4-6"></a>

### Canadian testing costs, turnaround, and out-of-pocket costs: trofinetide reimbursement review

> “The total cost of MECP2 testing is approximately $1,307.45 per sample, which includes:”
> “$1,172.42 for Sanger sequencing and MLPA (i.e., $586.21 for each test processed in Alberta)”
> “The anticipated cost of ordering an MECP2 sequence and CNV detection test using NGS is US$990;”
> “according to a molecular testing inventory scan, the turnaround time in Alberta varies from 1 week to 2 weeks for urgent testing and from 6 weeks to 8 weeks for routine testing with both Sanger sequencing and MLPA.”
> “From the targeted jurisdictional survey, British Columbia indicated that in cases of MECP2 testing not approved for provincial reimbursement, out-of-pocket costs may be incurred by patients and their families.”
> “Repeat testing is not required once the MECP2 mutation status is confirmed.”
> “Based on the relatively low number of individuals estimated to be diagnosed with Rett syndrome each year, and because testing may already be routinely conducted in Canada to confirm the diagnosis of Rett syndrome, if trofinetide becomes funded, the provision of MECP2 testing is not anticipated to have a substantial impact on human or other health care resources.”

Source: [CDA-AMC trofinetide reimbursement review (2025)](https://canjhealthtechnol.ca/index.php/cjht/article/download/SR0829r/2969?inline=1)

Additional sources: [Kim et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/39255539/)

## Related pages
- [Lonimecgene renparvovec (TSHA-102): Rett syndrome](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Terms and abbreviations](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/terms-and-abbreviations.md)
- [Lonimecgene renparvovec (TSHA-102): Rett syndrome](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/executive-summary.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Product information and disease description](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/product-information-and-disease-description.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Clinical evidence](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/clinical-evidence.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Economic information and modeling report](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/economics) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/economics.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: References](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/references) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/references.md)
